Semax 5mg

Description

 Premium Semax (Met-Glu-His-Phe-Pro-Gly-Pro) for Sale | ≥97% Purity | 48-Hour Delivery Across EU & UK

---

Semax: The Synthetic Neuropeptide at the Forefront of Cognitive Research

eupeptidelap.co.uk is proud to present Semax 5mg, a premium research-grade synthetic heptapeptide manufactured to the highest analytical standards. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with Semax for sale that delivers exceptional purity, consistency, and documented quality for advanced studies in neuroprotection, cognitive enhancement, and neuroregeneration .

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic peptide analog of adrenocorticotropic hormone fragment ACTH(4-7) (Met-Glu-His-Phe) combined with the C-terminal tripeptide Pro-Gly-Pro, which affords increased resistance to peptidase activity . Unlike its parent hormone ACTH, Semax exhibits no hormonal activity, making it a valuable tool for investigating neuropeptide mechanisms without endocrine confounding variables . The peptide has a molecular formula of C₃₇H₅₁N₁₉O₁S and a molecular weight of 813.92 Da .

First developed and extensively studied in Russia, where it is included in the List of “Vital and Essential Drugs for Medical Application,” Semax has garnered international research attention for its remarkable neuroprotective and cognitive-supportive properties . Its ability to cross the blood-brain barrier and modulate key neurotrophic factors positions it as a compound of significant interest in neuroscience research.

For researchers seeking to buy peptide online EU for investigations into neurodegenerative diseases, cognitive function, stroke recovery, or spinal cord injury repair, eupeptidelap.co.uk offers this premium research compound with comprehensive documentation, including Certificates of Analysis and batch-specific purity data. Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our guaranteed 48 hour delivery peptide service ensures your research continues without interruption.

---

The Scientific Foundation of Semax Research

Molecular Structure and Design

Semax is a synthetic heptapeptide comprising the N-terminal adrenocorticotropic hormone fragment (4-7) (ACTH4-7) and the C-terminal Pro-Gly-Pro tripeptide . This structural engineering serves a crucial purpose: the Pro-Gly-Pro sequence confers increased resistance to enzymatic degradation, significantly extending the peptide’s biological half-life compared to unmodified neuropeptides . The amino acid sequence is H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, with all amino acids in the L-stereoisomer configuration .

Mechanisms of Action

Neurotrophin Modulation: One of Semax’s most well-characterized mechanisms is its ability to rapidly and dynamically regulate the expression of key neurotrophic factors. Studies demonstrate that a single intranasal administration of Semax significantly alters brain-derived neurotrophic factor (Bdnf) and nerve growth factor (Ngf) gene expression in rat hippocampus and frontal cortex within 20 minutes . The expression pattern is tissue-specific: levels decrease in the hippocampus while increasing in the frontal cortex initially, returning to baseline by 40 minutes, then showing significant elevation again by 90 minutes post-administration . This rapid, long-term, and region-specific activation of neurotrophin expression underlies Semax’s effects on neuronal survival, synaptic plasticity, and cognitive function.

NMDA Receptor Modulation: Research indicates that Semax’s nootropic and anxiolytic effects may be mediated through modulation of NMDA receptors in the hippocampus. Studies in BALB/c mice show that intranasal administration of Semax can alter the density of NMDA-receptor binding sites, contributing to its cognitive-enhancing properties .

Amyloid-Beta Aggregation Inhibition: Semax demonstrates concentration-dependent inhibition of amyloid β-1-40 (Aβ1-40) fiber formation both in buffer solutions and in the presence of model membranes . Particularly notable is its effect in the presence of copper ions (Cu²⁺), where it almost completely inhibits Aβ fiber formation at both low and high concentrations . This anti-amyloidogenic activity has significant implications for Alzheimer’s disease research.

Mu Opioid Receptor Interaction: Recent research has uncovered that Semax targets the μ opioid receptor gene Oprm1, promoting deubiquitination and functional recovery after spinal cord injury in female mice . This novel mechanism expands our understanding of Semax’s therapeutic potential beyond traditional neuroprotection.

Antioxidant and Antihypoxic Effects: Semax exhibits significant antioxidant and antihypoxic properties, protecting neural tissue from oxidative stress and oxygen deprivation . These effects are particularly relevant in models of cerebral ischemia and traumatic brain injury.

---

Key Research Applications

Alzheimer’s Disease and Amyloidosis Research

Semax has emerged as a promising candidate for Alzheimer’s disease research due to its multifaceted effects on key pathological features .

Cognitive Improvement in AD Models: A 2025 study using transgenic APPswe/PS1dE9/Blg mice—a well-established model of Alzheimer’s disease—demonstrated that intranasal Semax administration (50 μg/kg every other day for one month) significantly improved cognitive functions . Behavioral testing using the open field, novel object recognition, and Barnes maze tests confirmed that Semax-treated mice showed enhanced learning, memory, and spatial navigation compared to untreated controls .

Reduction of Amyloid Plaques: Histological examination revealed that Semax treatment reduced the number of amyloid inclusions in the cortex and hippocampus of the animals’ brains . This finding is supported by biophysical experiments showing Semax’s concentration-dependent inhibition of Aβ1-40 fiber formation .

Metal Ion Interactions: The presence of copper ions (Cu²⁺), which significantly influence amyloid aggregation kinetics, Semax demonstrates enhanced anti-aggregation properties, almost completely inhibiting fiber formation . This suggests Semax may be particularly effective in conditions where metal ion dyshomeostasis contributes to amyloid pathology.

Stroke and Cerebral Ischemia Research

Semax has been extensively studied in models of cerebral ischemia, where its neuroprotective properties are particularly pronounced .

Gene Expression Modulation: In rat brain focal ischemia models, Semax significantly alters gene expression patterns in damaged cortical tissues. Genome-wide expression analysis reveals that immune-related genes constitute over 50% of all Semax-modulated genes at the 24-hour timepoint, with genes encoding immunoglobulins and chemokines forming the most prominent groups .

Neurotrophin and Receptor Regulation: Research examining incomplete global ischemia demonstrates that Semax treatment affects the mRNA expression of neurotrophins (Ngf, Bdnf, Nt-3) and their receptors (TrkA, TrkB, TrkC, p75) in rat frontal cortex, hippocampus, and cerebellum . Maximal neuroprotective effects are observed in the hippocampus 12 hours after occlusion, where ischemia-induced decreases in gene expression are overcome by Semax treatment .

Vascular Effects: Under ischemic conditions, Semax influences the expression of genes that promote vascular system formation and functioning, contributing to improved blood flow and tissue perfusion in damaged brain regions .

Cognitive Enhancement and Nootropic Research

Semax’s ability to enhance learning, attention, and memory formation has been well-documented in both animal models and human studies .

Route-Dependent Effects: Research comparing intraperitoneal and intranasal administration in BALB/c and C57BL/6 mice reveals that the route of administration influences the predominance of nootropic versus anxiolytic effects . In BALB/c mice, the anxiolytic efficiency was higher after intraperitoneal injection, while the nootropic efficiency was higher after intranasal administration . This finding has important implications for experimental design in cognitive research.

Spatial Learning and Memory: The Barnes maze test, used to assess spatial learning and memory, demonstrates that Semax-treated APP/PS1 mice show significantly improved performance compared to untreated controls, indicating enhanced spatial navigation and memory consolidation .

Spinal Cord Injury Research

Recent groundbreaking research published in the British Journal of Pharmacology (2025) has identified a novel mechanism through which Semax promotes functional recovery after spinal cord injury .

Mu Opioid Receptor Deubiquitination: Semax targets the μ opioid receptor gene Oprm1, promoting deubiquitination and enhancing receptor function. This mechanism contributes to improved functional recovery in female mice following spinal cord injury, suggesting potential applications in neurotrauma research .

Traumatic Brain Injury Research

Studies using the “falling weight” model of mechanical brain injury in rats demonstrate that Semax treatment (administered intranasally 1 hour post-injury, then twice daily for 4 days) significantly attenuates injury-induced body weight loss and preserves neurological function .

Immune Function Preservation: Traumatic brain injury leads to suppression of lymphocyte proliferative activity and decreased NK cell cytotoxicity. In animals treated with Semax, there was no significant suppression of NK cell cytotoxicity, and lymphocyte proliferative activity was restored to control levels by day 14 post-injury .

Locomotor Activity: Semax-treated animals showed higher locomotor activity compared to untreated controls, and the reduction in freezing duration indicated a beneficial sedative effect .

Neuroinflammation Research

Semax’s profound effects on immune-related gene expression position it as a valuable tool for neuroinflammation research . Temporal analysis reveals distinct patterns: at 3 hours post-ischemia, Semax selectively modulates genes affecting immune cell activity; at 24 hours, there is a dramatic increase in immune-related gene modulation, constituting over 50% of all Semax-affected genes . This immunomodulatory profile suggests Semax may exert its neuroprotective effects partly through optimization of immune responses in damaged neural tissue.

---

Quality Assurance: Setting the Standard for Research Compounds

Manufacturing Excellence

eupeptidelap.co.uk sources Semax 5mg from certified GMP facilities with rigorous quality control protocols:

• HPLC Purity Analysis: >97% purity verified by reverse-phase high-performance liquid chromatography

• Mass Spectrometry Verification: Molecular weight confirmation (813.92 Da) via LC-HRMS

• Batch-Specific Certificates of Analysis: Complete documentation for each production run

• Sterile Manufacturing: Lyophilized with no additives; sterile filtered

• Research-Use Only (RUO) Labeling: Full compliance with research compound regulations

Chemical and Product Specifications

Stability and Handling Guidelines

Lyophilized Powder Storage: Store lyophilized Semax powder below -18°C in a dry, dark environment, protected from light and moisture, and kept desiccated . While the peptide is stable at room temperature for up to 3 weeks, refrigeration or freezing is recommended for extended storage .

Reconstitution Protocol:

1. Allow vial and solvent to reach ambient temperature before opening to prevent condensation

2. Reconstitute using sterile 18MΩ-cm H₂O at not less than 100 μg/ml, which can then be further diluted to other aqueous solutions

3. Inject solvent slowly down the inside wall of the vial to minimize foaming

4. Gently swirl or roll the vial until fully dissolved—do not shake vigorously

5. Label the vial with the date of reconstitution

6. Refrigerate immediately at 4°C

Reconstituted Solution Storage: Store reconstituted Semax at 4°C for 2-7 days . For long-term storage, aliquot into single-use portions, add a carrier protein (0.1% HSA or BSA), and store below -18°C . Prevent repeated freeze-thaw cycles .

Common Administration Routes for Research:

• Intranasal: Frequently used for direct CNS delivery; shown to enhance nootropic effects

• Intraperitoneal: Used for systemic administration; associated with enhanced anxiolytic effects

• Subcutaneous: Alternative parenteral route

Protection from Light and Moisture:

• Store in original packaging protected from light

• Keep vials tightly sealed when not in use

• Allow refrigerated vials to reach room temperature before opening to prevent condensation

 

Key Benefits

• Premium Quality Manufacturing: GMP-certified production, >97% HPLC-verified purity

• Clinically Validated Peptide: Extensively studied in neurological research; included in Russian List of “Vital and Essential Drugs”

• Neurotrophin Modulation: Rapidly activates Bdnf and Ngf expression in hippocampus and frontal cortex

• Alzheimer’s Disease Research: Reduces amyloid plaques and improves cognitive function in AD models

• Amyloid-β Aggregation Inhibition: Concentration-dependent inhibition of Aβ1-40 fiber formation; nearly complete inhibition in presence of Cu²⁺

• Stroke and Ischemia Research: Modulates gene expression in ischemic brain tissue; enhances vascular gene expression

• Spinal Cord Injury Research: Promotes functional recovery via Oprm1 deubiquitination

• Traumatic Brain Injury: Preserves neurological function and immune competence post-injury

• Cognitive Enhancement: Improves learning, attention, and memory formation in animal models

• Route-Dependent Effects: Nootropic effects enhanced with intranasal administration

• NMDA Receptor Modulation: Alters NMDA-receptor density in hippocampus

• Immune Modulation: Influences expression of immunoglobulins and chemokines in neural tissue

• Neuroinflammation Research: Profound effects on immune-related gene expression

• Antioxidant Properties: Exhibits significant antioxidant and antihypoxic effects

• Favorable Safety Profile: No hormonal activity; well-tolerated in research settings

• Comprehensive Documentation: Certificates of Analysis with batch-specific purity data

• 48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe

• Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility

• EU Sourced: Available from within the European Union

---

Frequently Asked Questions

Q: What is Semax and how does it work?

A: Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-7) with a C-terminal Pro-Gly-Pro tripeptide that enhances enzymatic stability . It works through multiple mechanisms including rapid modulation of neurotrophin expression (BDNF, NGF), NMDA receptor interaction, inhibition of amyloid-β aggregation, and modulation of immune-related genes in neural tissue .

Q: What purity level can I expect when I buy Semax from eupeptidelap.co.uk?

A: All Semax 5mg from eupeptidelap.co.uk is tested to >97% purity by RP-HPLC . Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.

Q: What is the molecular weight and sequence of Semax?

A: Semax has a molecular weight of 813.92 Da and the amino acid sequence H-Met-Glu-His-Phe-Pro-Gly-Pro-OH . Its molecular formula is C₃₇H₅₁N₁₉O₁S .

Q: How should I reconstitute Semax for research use?

A: Reconstitute lyophilized Semax in sterile 18MΩ-cm H₂O at not less than 100 μg/ml, which can then be further diluted to other aqueous solutions . Inject solvent slowly, gently swirl—do not shake. After reconstitution, store at 4°C for 2-7 days. For long-term storage, aliquot into single-use portions, add a carrier protein (0.1% HSA or BSA), and store below -18°C .

Q: How should I store Semax for long-term stability?

A: Store lyophilized Semax powder below -18°C, protected from light and moisture, and kept desiccated . While stable at room temperature for up to 3 weeks, refrigeration or freezing is recommended for extended storage .

Q: What is the half-life of Semax?

A: Semax has a half-life of approximately 30 minutes . Its C-terminal Pro-Gly-Pro sequence confers increased resistance to enzymatic degradation compared to unmodified neuropeptides .

Q: What research areas commonly use Semax?

A: Semax is widely used in Alzheimer’s disease research , stroke and cerebral ischemia studies , cognitive enhancement and nootropic research , spinal cord injury research , traumatic brain injury studies , and neuroinflammation research .

Q: Does Semax cross the blood-brain barrier?

A: Yes, Semax is capable of crossing the blood-brain barrier, making it suitable for investigating central nervous system effects. Intranasal administration is frequently used in research for direct CNS delivery .

Q: What is the difference between intranasal and intraperitoneal administration in research?

A: Research in BALB/c mice shows that route of administration influences the predominance of effects: nootropic (cognitive-enhancing) effects are more pronounced with intranasal administration, while anxiolytic effects are more pronounced with intraperitoneal injection .

Q: Do you ship Semax to EU countries?

A: Yes. As a dedicated EU peptide supplier, we ship Semax 5mg to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use protective packaging to maintain compound integrity during transit.

Q: What documentation do you provide with Semax orders?

A: Every order includes a Certificate of Analysis (COA) with batch-specific purity data. Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification.

Q: What is the evidence for Semax in Alzheimer’s disease research?

A: A 2025 study in transgenic APPswe/PS1dE9/Blg mice demonstrated that intranasal Semax administration significantly improved cognitive functions (open field, novel object recognition, Barnes maze tests) and reduced the number of amyloid inclusions in cortex and hippocampus . Biophysical experiments confirm Semax’s concentration-dependent inhibition of Aβ1-40 fiber formation, with near-complete inhibition in the presence of copper ions .

Q: Does Semax affect neurotrophin expression?

A: Yes. Studies demonstrate that a single intranasal administration of Semax significantly alters brain-derived neurotrophic factor (Bdnf) and nerve growth factor (Ngf) gene expression in rat hippocampus and frontal cortex within 20 minutes, with a characteristic temporal pattern .

Q: Do you offer bulk quantities of Semax for institutional research?

A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs.

---

Advance Your Research with Semax 5mg

eupeptidelap.co.uk is your trusted source for Semax 5mg, the premium choice for researchers investigating neuroprotection, cognitive enhancement, neurodegeneration, and neural repair mechanisms. With extensive peer-reviewed literature spanning Alzheimer’s disease, stroke, spinal cord injury, and traumatic brain injury models, Semax represents one of the most versatile and well-characterized neuropeptides in the research community. ...........................................

Whether you are exploring amyloid-β aggregation pathways, designing neuroprotection studies, investigating cognitive enhancement mechanisms, or researching spinal cord injury repair, our rigorously tested compound provides the quality and consistency your work demands.  .  .  .  .  . .   .  .  . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 

Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.